Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Organisation › Details

Pieris AG

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create safer, more efficacious and more convenient protein therapeutics. Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches. Pieris' pipeline ranges from its Phase I compound, PRS-050 (anti-VEGF, oncology), to multiple Anticalins in preclinical development. The company has four ongoing discovery and development collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan. Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. *

 

Period Start 2001-01-01 established_pre
Period End 2017-08-21 reorganised before
  Group Pieris (Group)
  Today Pieris Pharmaceuticals GmbH
  Predecessor Pieris Proteolab AG
  Successor Pieris Pharmaceuticals GmbH
Products Industry Anticalin® scaffold technology
  Industry 2 Anticalin® therapeutic protein
Persons Person Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)
  Person 2 Schalper, Claus (XL-protein 201410 Managing Director (CEO) before Pieris 201101 CFO)
     
Region Region Freising
  Country Germany
  Street 30 Lise-Meitner-Str.
  City 85354 Freising-Weihenstephan
  Tel +49-8161-1411-400
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
     
    * Document for �About Section�: Pieris AG. (10/19/11). "Press Release: Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin Pipeline Development". Freising.
     
   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Pieris (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top